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Abstract: Novel tissue-engineered magnetic fibrin hydrogel scaffolds were prepared by the 
interaction of thrombin-conjugated iron oxide magnetic nanoparticles with fibrinogen. In 
addition, stabilization of basal fibroblast growth factor (bFGF) was achieved by the covalent and 
physical conjugation of the growth factor to the magnetic nanoparticles. Adult nasal olfactory 
mucosa (NOM) cells were seeded in the transparent fibrin scaffolds in the absence or presence 
of the free or conjugated bFGF-iron oxide nanoparticles. The conjugated bFGF enhanced 
significantly the growth and differentiation of the NOM cells in the fibrin scaffolds, compared to 
the same or even five times higher concentration of the free bFGF. In the presence of the bFGF-
conjugated magnetic nanoparticles, the cultured NOM cells proliferated and formed a three-
dimensional interconnected network composed mainly of tapered bipolar cells. The magnetic 
properties of these matrices are due to the integration of the thrombin- and bFGF-conjugated 
magnetic nanoparticles within the scaffolds. The magnetic properties of these scaffolds may 
be used in future work for various applications, such as magnetic resonance visualization of 
the scaffolds after implantation and reloading the scaffolds via magnetic forces with bioactive 
agents, eg, growth factors bound to the iron oxide magnetic nanoparticles.
Keywords: thrombin, fibroblast growth factor, fibrin scaffold, iron oxide nanoparticles, tissue 
engineering, magnetism, bioactive nanoparticle
Introduction
Fibrin hydrogels are common materials being explored as matrices for tissue engi-
neering applications, eg, tissue engineering of adipose, cardiovascular, ocular, 
muscle, liver, skin, cartilage, bone and neuronal tissues.1–4 The fibrin hydrogels 
combine some important advantages such as inherent flexibility, soft, high seeding 
efficiency, and uniform cell distribution. In addition, they cast easily into different 
three-dimensional (3D) shapes and can be injected directly into the site of an injury 
for in situ gelation. Furthermore, fibrin contains cell-binding sites and thus enhances 
cell adhesion.5,6 Fibrin hydrogels are natural polymers made by mixing two blood 
coagulation components, fibrinogen and thrombin, which form a clot upon mixing. In 
human plasma, the half-life of thrombin is shorter than 15 seconds due to tight control 
by protease inhibitors and components of the vessel’s wall.7 In previous studies, we 
have demonstrated that appropriate conjugation of thrombin to iron oxide (γ-Fe2O3) 
magnetic nanoparticles preserved the thrombin-clotting activity, stabilized the throm-
bin against its major inhibitor, antithrombin III, and improved its storage stability.8,9 
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In the present study, these thrombin-conjugated γ-Fe2O3 
nanoparticles were used to fabricate novel magnetic fibrin 
hydrogel scaffolds.
Iron oxide nanoparticles are of great interest due to their 
magnetic properties, high surface area-to-volume ratio, 
biocompatibility, relative nontoxicity, and biodegradability. 
The use of iron oxide magnetic nanoparticles for various 
biomedical applications, eg, hyperthermia, diagnostics, cell 
labeling and sorting, DNA separation, magnetic resonance 
imaging (MRI) and X-ray contrast agents, magnetic stimuli-
sensitive polymeric systems, and gene and drug delivery, 
have already been demonstrated.10–18 Recent studies in the 
tissue-engineering field proposed to produce magnetic scaf-
folds by integration of nonmodified iron oxide nanoparticles 
in scaffolds made of various materials. For example, Bock 
et al19 succeeded in transforming standard commercial scaf-
folds, made of hydroxyapatite–collagen and pure collagen, 
to magnetic scaffolds by dip-coating the scaffolds in aqueous 
ferrofluids containing iron oxide nanoparticles. Hu et al20 
and Sivudu et al21 fabricated magnetic hydrogel scaffolds 
by in situ development of iron oxide nanoparticles in gela-
tin or polyacrylamide hydrogels, respectively. It has been 
suggested to use the magnetic properties of these scaffolds 
for monitoring the scaffolds after implantation by MRI or 
X-ray, and for reloading the scaffolds after implantation with 
bioactive agents, such as growth factors, stem cells, or other 
bioactive reagents that can be bound to magnetic iron oxide 
nanoparticles.17,19,22,23
In order to enhance cell regeneration, scaffolds are 
often designed as platforms for the delivery of bioactive 
molecules such as growth factors, angiogenic factors, and 
differentiation factors.1,2,24,25 For example, basal fibroblast 
growth factor (bFGF, also known as FGF-2) is a mitogenic 
polypeptide which induces cell divisions in a variety of cell 
types including skin, blood vessel, muscle, adipose, cartilage, 
and bone tissues.26,27 It also promotes cell proliferation and 
differentiation in cultures of mouse and human olfactory 
epithelium.28,29 In addition, bFGF has been shown to promote 
neuron survival, nerve fiber outgrowth, and proliferation 
of neuronal precursor cells in cultures.26,27,30,31 The main 
disadvantage of free bFGF is its short in vivo half-life of 
about 3–10 minutes due to rapid enzymatic degradation, 
which leads to loss of biological activity and functions.26,32 
To achieve a satisfactory performance, growth factors were 
adsorbed onto, or encapsulated within, nanomaterials to 
protect their stability and biological activity.31–33
A wide range of cell types have been investigated 
for tissue-engineering applications. For example, adult 
nasal olfactory mucosa (NOM) cells are primary cells 
of interest for implantation into spinal cord injuries.3,34–39 
NOM cells are often derived through a simple nasal 
biopsy from the patient prior to implantation in his or 
her own body, which eliminates rejection. The NOM is a 
heterogeneous complex of cells which includes, among 
others, neuronal progenitor cells (adult stem cells), and 
glial olfactory ensheathing cells (OECs).35 NOM cells 
have been investigated extensively to see if they have the 
same capacity to promote neuronal regeneration follow-
ing spinal cord injuries.34 Some of these studies showed 
that the transplantation of OECs could promote axonal 
regeneration and functional recovery through their spe-
cific glia properties, namely, by secretion of neurotrophic 
factors (such as nerve growth factor [NGF], brain-derived 
neurotrophic factors [BDNF] and glial cell-derived 
neurotrophic factor [GDNF]) and extracellular matrix 
molecules (such as N-CAM and laminin).3,34,36,37 Recent 
studies indicate that the transplantation of a “pure” OEC 
population is insufficient for attaining complete recovery 
of spinal cord   injuries. A better recovery of these injuries 
can be attained using a complex of NOM cells, including, 
apart from the OECs, neuronal progenitor cells from the 
neuroepithelium.35,37
We describe herein the development of new magnetic 
fibrin hydrogel scaffolds intended for the cultivation and 
implantation of NOM cells into spinal cord injuries. The 
scaffolds are obtained by the interaction of thrombin-con-
jugated γ-Fe2O3 magnetic nanoparticles and fibrinogen. In 
addition, we describe a new method for stabilization of bFGF 
by covalent or physical conjugation to γ-Fe2O3 nanoparticles. 
Adult NOM cells were seeded in the magnetic fibrin scaf-
folds in the absence or presence of the free or conjugated 
bFGF-iron oxide nanoparticles. The aim of this study was to 
characterize these novel scaffolds, and to examine the influ-
ence of the bFGF-conjugated nanoparticles on the growth 
of NOM cells seeded in these scaffolds, as compared with 
the free factor.
Materials and methods
Materials
The following analytical-grade chemicals were purchased 
from commercial sources and used without further 
purification: ferric chloride hexahydrate, hydrochloric 
acid (1 M), sodium hydroxide (1 M), sodium nitrite,   
glutaraldehyde, paraformaldehyde (4%), Triton X-100, 
gelatin from porcine skin, human serum albumin (HSA), 
bovine serum   albumin (BSA), rhodamine B isothiocyanate 
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(RITC), divinyl sulfone (DVS), triethylamine (TEA), 
bovine fibrinogen, bovine fibronectin, aprotinin, D-glucose 
and poly-L-lysine (PLL; MW 30,000–70,000) from 
Sigma (Israel); recombinant human bFGF from PeproTech 
(Israel); bovine thrombin and factor XIII from Merck 
(Israel); Midi-MACS magnetic   columns from Miltenyi 
Biotec GmbH (Germany); bicarbonate buffer (BB; 0.1 
M, pH 8.4), phosphate-buffered saline (PBS free of Ca+2 
and Mg+2; 0.1 M, pH 7.4), Dulbecco’s modified Eagle’s 
medium–nutrient mixture F-12 (DMEM–F12), fetal 
calf serum (FCS), gentamicin, glutamine, Hepes, and 
trypsin–EDTA solution (0.25%) from Biological-Industries 
(Israel); Bio-Rad protein assay kit (Bradford) from Bio-
Rad (Germany); tissue culture plates (24 wells) and 
35 cm   culture plates from JET BioFiL (Israel); chitosan 
microcarriers (MCs) from Medovent GmbH (Germany). 
Water was purified by passing deionized water through 
an Elgastat Spectrum reverse osmosis system (Elga, High 
Wycombe, UK).
Synthesis of γ-Fe2O3 nanoparticles
Iron oxide nanoparticles of 19.8 ± 4.7 nm diameter were 
prepared via nucleation and growth mechanism, as described 
previously.10,40 Briefly, 240 mg of gelatin were dissolved in 
80 mL of water at 60°C. Then, 160 µL of a Fe+2 solution 
(10 mmol in 5 mL of 0.1 N HCl) and 57.6 µL of a sodium 
nitrite solution (7.27 mmol in 5 mL H2O) were added to 
the shaken gelatin solution. For nucleation, titration with 
sodium hydroxide (1 M) until a pH of 9.5 was performed. 
This procedure was repeated successively four more times. 
The reaction mixture was then shaken at 60°C for an addi-
tional hour. The formed γ-Fe2O3 magnetic nanoparticles were 
then washed from nonmagnetic waste with deionized water 
by magnetic columns, via the high gradient magnetic field 
(HGMF) technique.41
Precipitation of albumin coating onto  
the γ-Fe2O3 nanoparticles
Albumin coating onto the γ-Fe2O3 nanoparticles was prepared 
by a precipitation mechanism as described previously.9,42 
Briefly, 5 mg of BSA or HSA were added to 4 mL of the 
γ-Fe2O3 nanoparticles dispersed in water (2.5 mg/mL). The 
reaction mixture was subsequently shaken at pH 9.5 and 60°C 
for 18 hours, and then cooled gradually to room temperature. 
The obtained γ-Fe2O3≈BSA or γ-Fe2O3≈HSA nanoparticles   
(≈ is the symbol for the albumin coating obtained by precipi-
tation) were then washed from excess albumin with PBS by 
magnetic columns.
Thrombin conjugation to the γ-Fe2O3 
nanoparticles
Thrombin was physically conjugated to the γ-Fe2O3 nanopar-
ticles to increase its stability and thus to prolong its activity, 
as described previously.8,9,42 Briefly, 7 mg of thrombin were 
added to 4 mL of the γ-Fe2O3≈BSA nanoparticles dispersed in 
PBS (2.5 mg/mL). The reaction mixture was then shaken at 
4°C for 18 hours. The obtained thrombin-conjugated γ-Fe2O3 
nanoparticles (γ-Fe2O3≈BSA∼Thrombin, ∼ is the symbol for 
physical conjugation) were then washed from excess throm-
bin with PBS (0.1 M, pH 7.3) by magnetic columns.
bFGF conjugation to the γ-Fe2O3 
nanoparticles
bFGF was conjugated, for stabilization, to the γ-Fe2O3 
nanoparticles by two main routes, covalent and physical 
conjugation, as follows:
Covalent conjugation of bFGF
The covalent conjugation was accomplished through the 
following steps:
Synthesis of DVS-derivatized γ-Fe2O3 nanoparticles
γ-Fe2O3 nanoparticles were functionalized with activated 
double bonds via the interaction between the primary amine 
groups of the gelatin coating of the γ-Fe2O3 nanoparticles and 
DVS. Briefly, 12 µL DVS were added to 1 mL of the γ-Fe2O3 
nanoparticles dispersed in BB (3 mg/mL, pH 8.4). TEA was 
then gradually added until a pH of 10.5 was reached. The 
reaction mixture was then shaken at 60°C for 18 hours. The 
formed DVS-derivatized γ-Fe2O3 nanoparticles were then 
washed from excess DVS with BB by magnetic columns.
Covalent conjugation of bFGF to the DVS-derivatized 
nanoparticles
Covalent conjugation of bFGF to the γ-Fe2O3 nanoparticles 
was accomplished via the interaction of the amino and/
or thiol groups of the growth factor with the activated 
double bonds on the nanoparticle surface via the Michael 
addition reaction. Briefly, 125 µL of a bFGF PBS solution 
(0.4 mg/mL, pH 7.4) were added to 125 µL of the DVS 
derivatized nanoparticles dispersed in BB (4 mg/mL, pH 8.4) 
at a nanoparticle/bFGF weight ratio of 10. The reaction 
mixture was then shaken at room temperature for 18 hours. 
Blocking of the residual double bonds was accomplished by 
adding 1% glycine (w/v) and then shaking for an additional 
hour. The obtained covalently bFGF-conjugated γ-Fe2O3 
nanoparticles (γ-Fe2O3 – bFGF nanoparticles; – is the   symbol 
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for the   covalent   conjugation) were then washed from non-
magnetic waste with PBS by magnetic columns.
Physical conjugation of bFGF
The physical binding of bFGF to the γ-Fe2O3 nanoparticles 
was accomplished by the physical interaction of bFGF with 
the γ-Fe2O3≈HSA nanoparticles. Briefly, 125 µL of a bFGF 
PBS solution (0.4 mg/mL, pH 7.4) were added to 125 µL of 
the γ-Fe2O3≈HSA nanoparticles dispersed in PBS (4 mg/mL, 
pH 8.4) at a nanoparticle/bFGF weight ratio of 10. The 
reaction mixture was then shaken at room temperature for 
18 hours. The obtained bFGF physically-conjugated nanopar-
ticles (γ-Fe2O3∼bFGF) were then washed from nonmagnetic 
waste with PBS by magnetic columns.
Binding yield and concentration  
of thrombin and bFGF bound  
to the γ-Fe2O3 nanoparticles
The concentration of the thrombin and the bFGF conjugated 
to the γ-Fe2O3 nanoparticles were determined by measuring 
the unbound thrombin or bFGF using the Bradford assay43 
and subtracting it from the initial concentration. The binding 
yield was calculated by multiplying the ratio between the 
concentration of the bound protein to the initial concentra-
tion by 100.
Thrombin and bFGF leakage extent
The leakage of bound thrombin and bFGF from the γ-Fe2O3 
nanoparticles into PBS containing 4% HSA (equivalent to 
the physiologic concentration of HSA) was evaluated using 
the following procedure: thrombin-conjugated nanoparticles 
and bFGF-conjugated nanoparticles dispersed in PBS con-
taining 4% HSA (2 mg nanoparticles/mL) were shaken at 
room temperature for 7 hours. Then, the nanoparticles were 
extracted from the supernatant using the HGMF technique. 
The concentration of the bFGF leaked to the supernatant was 
measured using human bFGF ELISA kit (Biotest, Israel). 
The thrombin leakage extend was measured as described 
previously.9
Isolation of NOM cells from adult rats
The NOM cells were derived from the olfactory mucosa of 
Lewis inbred rats (Harlan, Israel), as described   previously.38 
Adult Lewis rats (250 g) were nasally infused with 
0.7% Triton X-100 in both nostrils 4 days prior to their 
scarification. The Triton X-100 causes a moderate   damage 
to the neuroepithelium, which thereby encourages a 
large number of neurons to be obtained, following an active 
  reconstruction by the neuronal precursor cells in a culture. 
  Prior to the NOM dissection, cardiac perfusion of the rats 
was made with 60 mL of saline. All the experiments were 
carried out under the Animals’ Care and Use Committee, 
which is recognized by the Israeli authorities for animal 
experimentation. The dissected NOM tissue was fragmented, 
separated from the bones under a stereomicroscope and 
washed several times with an ice-cold culture medium 
(composed of 90% DMEM-F12, 10% FCS, 6 g/L D-glucose, 
2 nM glutamine and 25 µg/mL gentamicin). The NOM 
fragments were then enzymatically dissociated in a 0.25% 
trypsin-EDTA solution for 30 minutes.
Cultivation of adult rat NOM cells  
in the magnetic fibrin hydrogel scaffolds
The NOM cells were seeded and grown in the magnetic 
fibrin hydrogel scaffolds by two tissue cultivation methods. 
In the first method, dissociated cells were grown first as a 
two-dimensional stationary culture for three weeks.38 The 
cells were then transferred and seeded in the magnetic fibrin 
hydrogel scaffolds, in the absence or presence of free or 
conjugated bFGF, as described below. In the second method, 
the NOM cells were cultured for a week in suspension 
attached to positively-charged chitosan microcarriers (MCs), 
in the absence or presence of free or conjugated bFGF 
nanoparticles. Subsequently, the formed floating cells/growth 
factors/MCs aggregates were transferred and seeded in the 
magnetic fibrin scaffold. The detailed preparation procedure 
of the NOM cells/free or conjugated bFGF nanoparticles/
MCs aggregates is described below.
Preparation of NOM cells/free or 
conjugated bFGF nanoparticle/MCs 
aggregates
0.2 mL of 2% (w/v) chitosan MCs (4 mg) suspended in 
PBS were added to each well of a 24-well culture plate. 
Subsequently, each well was enriched with 10 µL (10 µg 
bound bFGF/well) of the γ-Fe2O3-bFGF nanoparticles dis-
persed in PBS, and the mixtures were then incubated at 37°C 
for 1 hour. To each well, 500 µL of the NOM cell suspension 
were then added (5 × 106 cells/well) and incubated with the 
γ-Fe2O3-bFGF nanoparticle/MCs aggregates at 37°C for 
1 hour. Then, each well received 1.3 mL of culture medium 
and were incubated for an additional 7 days. Subsequently, 
100 µL of the cell/γ-Fe2O3-bFGF nanoparticle/MCs aggre-
gates of each well were transferred and seeded in the fibrin 
scaffolds, as described below. Similar experiments were also 
performed in the presence of naked γ-Fe2O3   nanoparticles 
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(control), γ-Fe2O3∼bFGF nanoparticles, and different 
concentrations of the free bFGF, eg, the same concentration 
as the conjugated nanoparticles and 5 and 10 times higher.
Preparation of the magnetic fibrin 
hydrogel scaffolds and cultivation  
of the dissociated cells in the scaffolds
The following components were added to each well of the 
24-well culture plate: 100 µL of the cell suspension (1 × 106 
cells/well), 150 µL of bovine fibrinogen (100 mg/mL PBS), 
155 µL of a culture medium, 60 µL of a CaCl2 aqueous solu-
tion (25 mM), 5 µL of Factor XIII (200 µg/mL PBS) and 
8 µL of aprotinin (6720 KUI/mL PBS). In the experiments 
aimed at studying the effect of the nonconjugated γ-Fe2O3 
nanoparticles (control) and the free or conjugated-bFGF on 
the proliferation and differentiation of the NOM cells, γ-Fe2O3 
nanoparticles and free or conjugated growth factors were also 
added to each well (0.5 µg of free or conjugated factor/well). 
Finally, 50 µL of the thrombin-conjugated nanoparticles 
(360 µg of thrombin bound to 0.5 mg of nanoparticles/mL 
PBS) were added to each well. The mixture was then allowed 
to clot (in about 2 minutes). After clotting, 1 mL of the culture 
medium was added to each fibrin clot, and the cells were 
incubated at 37°C in a CO2 incubator. The culture medium 
was changed every 3 days. The cultures were performed in 
triplicate for each type of treatment.
For a quantitative determination of the effect of the 
free/conjugated bFGF on the growth of the NOM cells in 
the magnetic fibrin scaffolds, three random nonoverlapping 
pictures of each culture were taken on different days of the 
cultivation, using phase-contrast microscopy (Olympus 
BX60 F5 microscope; Eisenberg Bros, Israel). The cells 
were then counted using ImageJ software, and the average 
and the standard deviations were calculated.
Cultivation of the cell/bFGF/MCs 
aggregates in the magnetic fibrin  
hydrogel scaffolds
This cultivation process was performed similarly to the culti-
vation process described above, substituting the 100 µL of the 
dissociated cells suspension and the free or conjugated factors 
for 100 µL of the cell/bFGF/MCs aggregates’ suspension.
Immunofluorescent staining
The characterization of the NOM cells was accomplished 
through immunofluorescent staining. Samples to be ana-
lyzed were fixed for 15 minutes with 4% of paraformal-
dehyde at room temperature and then washed three times 
with PBS. The fixed cells were permeabilized with 0.1% 
of Triton X-100 in PBS and then immunoblocked (to avoid 
nonspecific staining) with a background buster solution 
(Innovex Biosciences, Richmond, CA) for 1 hour at room 
temperature. The samples were then incubated overnight 
at 4°C with the respective primary antibodies in PBS. The 
following primary antibodies were used: rabbit anti-tubulin 
beta 3, clone EP1331Y (β3Tub, neuronal marker, 1:200, 
catalog #NB110-576-10; Novus Biologicals); rabbit anti-
neurofilament medium (NF, neuronal marker, 1:400, catalog 
#NB300-133; Novus Biologicals), mouse anti-S100B (glia 
marker, 1:80, catalog # DM111-05; Acris Antibodies) and 
mouse anti-nestin, clone rat-401 (neurofilament protein, 
neuronal precursor marker, 1:100, catalog #sc-33677; Santa 
Cruz Biotechnology). The samples were subsequently rinsed 
with PBS and incubated overnight at 4°C with the appropriate 
dye-conjugated secondary antibodies (DyLight 649-conju-
gated donkey anti-mouse IgG, 1:200, catalog #715-495-151; 
DyLight 488-conjugated donkey anti-rabbit IgG, 1:200, 
catalog #711-485-152; both from Jackson ImmunoResearch). 
Finally, the samples were washed again with PBS, and the 
nuclei of the cells were stained (blue) and mounted with 
DAPI-Fluoromount-G. Control experiments were performed 
similarly, but in the absence of the primary antibodies. All of 
the images were observed by a Nikon 90i microscope (Nikon, 
USA) and processed using the Cell-R software under the same 
conditions (exposure time and magnification).
Cell adhesion
Purified NOM cells were seeded in 24-well culture plates 
on top of the magnetic fibrin hydrogel scaffolds, or in PLL-
coated wells, or in noncoated wells (control). The fibrin 
coating was performed as follow: a mixture containing 
120 µL of fibrinogen (100 mg/mL PBS), 225 µL of a culture 
medium, and 50 µL of a CaCl2 aqueous solution (25 mM) was 
added to each well. Then, 40 µL of the thrombin-conjugated 
nanoparticles (360 µg of thrombin bound to 0.5 mg nano-
particles/mL PBS) were added to each well, and the mixture 
was allowed to clot (in a few minutes). The PLL coating 
was performed as follow: 500 µL of a PLL solution (0.1% 
in PBS) were add to each well and incubated at 37°C for 
1 hour. The coated wells were then washed three times with 
the culture medium. After completion of the coating process, 
ten thousand (1 × 104) NOM cells suspended in 0.5 mL of 
the culture medium were seeded in each uncoated and coated 
well. Two, 4, 6, and 24 hours after the cell culturing, the wells 
were carefully rinsed three times with the culture medium 
to remove the nonadherent cells. To quantify the number 
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of adherent cells, pictures of five random nonoverlapping 
fields of each well were taken using a phase-contrast micro-
scope. The attached cells were then counted using ImageJ 
software, and the average and the standard deviations were 
calculated.
Characterization
Electron microscopy
Transmission electron microscopy (TEM) pictures were 
obtained with a FEI Tecnai C2 BioTWIN electron micro-
scope with a 120 kV accelerating voltage. High-resolution 
TEM (HRTEM) images were obtained by employing a 
JEOL-2100 device with a 200 kV accelerating voltage. The 
nanoparticle samples for TEM and HRTEM were prepared 
by placing a drop of a diluted sample on a 400-mesh carbon-
coated copper grid or on a carbon-coated copper lacy grid. 
The average size and size distribution of the dry particles 
were then determined by measuring the diameter of more 
than 200 particles with image analysis software, AnalySIS 
Auto (Soft Imaging System GmbH, Germany). Samples 
of the magnetic fibrin scaffolds for TEM analysis were 
obtained as follows: the reagents used to prepare the fibrin 
hydrogels were mixed, as described in the experimental part, 
in the absence of the cells and diluted 100× in PBS. A drop 
of the diluted sample was then placed carefully on a 400-
mesh carbon-coated copper grid, and allowed to form a thin 
layer of fibrin fibers for 1 minute. The excess solution was 
then removed with a filter paper. The 3D growth of the cells 
within the magnetic fibrin scaffolds was demonstrated by 
a scanning electron microscope (SEM) Model FEI Quanta 
250 FEG (OR). The samples for the SEM analysis were 
prepared as follow: following a desired period of cultivation, 
the cells in the scaffolds were fixed with 4% of glutaralde-
hyde in a PBS solution for 1 hour and then washed from 
excess reagents three times with PBS. In order to view the 
cells inside the scaffolds, the samples were cut into pieces 
using a scalpel blade. Then the fixed slices were dehydrated 
in series of 50%, 70%, 80%, 90%, and 100% ethanol/water 
solutions (v/v) for 10 minutes each. The residual ethanol 
was then removed using a series of 50%, 75%, and 100% 
(×3) Freon solutions in ethanol, for 10 minutes each. Finally, 
the samples were left for a few seconds to dry under air. The 
dried samples were mounted on aluminum stubs, sputter-
coated with carbon, and viewed with the SEM. Surface 
morphology of the cell/nanoparticle/MCs aggregates was 
also characterized with a SEM. The samples were fixed, as 
described above, and sputter-coated with gold in vacuum 
before viewing.
Magnetic measurements
Magnetic measurements were performed at room tempera-
ture using a vibrating sample magnetometer (VSM; Oxford 
Instruments, UK).
Statistical analysis
Statistical analysis was performed by Student’s t-test. The results 
are expressed as mean ± standard deviation (SD). P , 0.05 
was accepted as indicating the statistical significance.
Results and discussion
In the present study, the bFGF and the thrombin were stabi-
lized through their conjugation to γ-Fe2O3 nanoparticles of 
narrow size distribution (19.8 ± 4.7 nm) developed in our 
laboratory, as described previously.10,40
Figure 1 describes the general scheme through which 
the physical conjugation of thrombin and the physical and 
covalent conjugation of bFGF onto the surface of the γ-Fe2O3 
nanoparticles were performed. Figure 1 illustrates that the 
covalent conjugation of bFGF to the γ-Fe2O3 nanoparticles 
is based on the presence of gelatin thin layer on the surface 
of these nanoparticles, as shown in Figure 2A and B and 
described previously.44 The surface gelatin provides func-
tional groups, eg, primary amines and hydroxyls, through 
which functionalization of these nanoparticles with activated 
double bonds, via the Michael addition reaction, was accom-
plished with excess DVS. The residual activated double bonds 
of the γ-Fe2O3–DVS nanoparticles were then used for covalent 
binding of the bFGF to the surface of the nanoparticles, again 
via the Michael addition reaction. Blocking of the remaining 
double bonds of the γ-Fe2O3–bFGF nanoparticles was done 
with glycine, according to the experimental part.
The physical conjugation of thrombin and bFGF was 
performed in two main steps: the first step consisted of 
coating the nanoparticles dispersed in an aqueous continu-
ous phase with albumin (BSA or HSA) by a precipitation 
mechanism, according to the experimental part. The second 
step consisted of the physical conjugation of the thrombin 
or bFGF onto the albumin-coated γ-Fe2O3 nanoparticles. 
The physical conjugation of these bioactive molecules onto 
the albumin-coated layer is based on the fact that albumin 
is a carrier protein with a high affinity to various exogenous 
and endogenous compounds.45,46
The binding yield of albumin precipitated on the surface 
of the γ-Fe2O3 nanoparticles following addition of 5 mg 
albumin to 10 mg nanoparticles dispersed in PBS is 99.4% 
(496.7 µg albumin/mg nanoparticles), as determined by 
Bradford assay.9,43
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The concentrations and the conjugation yields of the 
thrombin and the bFGF bound to the γ-Fe2O3 nanoparticles are 
shown in Table 1. Table 1 indicates that the thrombin-binding 
yield is very high (97.5%). In addition, Table 1 shows that the 
binding yield of both the covalent and physical conjugation of 
the bFGF to the nanoparticles is similar and very high (95.4% 
and 96.9%, respectively). The high binding yields values of the 
covalent binding may indicate that in addition to the covalent 
binding, physical adsorption of the bFGF onto the surface of 
the nanoparticles may also be involved.
The thrombin leakage from the γ-Fe2O3 ≈ BSA∼thrombin 
nanoparticles into PBS containing 4% HSA was negligible.9 
Similarly, the leakage of both the covalently and the physi-
cally bound bFGF into PBS containing 4% HSA was not 
detected by the bFGF ELISA kit.
The organic coatings on the γ-Fe2O3 nanoparticles were 
visualized by HRTEM. Figure 2 demonstrates the gelatin, 
gelatin≈BSA, and the gelatin≈BSA∼thrombin coatings 
on the crystalline core of the γ-Fe2O3, γ-Fe2O3≈BSA, and 
γ-Fe2O3≈BSA∼thrombin nanoparticles, respectively. Careful 
measurements indicated that the gelatin, BSA, and thrombin 
thicknesses under the described experimental conditions 
were: 3.8 ± 1.1, 0.8 ± 0.3 and 3.1 ± 0.4 nm, respectively.
In previous studies, the thrombin-conjugated γ-Fe2O3 
nanoparticles were used for hemostasis and wound healing.9,42 
In the present study, these nanoparticles were used for the 
fabrication of the magnetic fibrin hydrogel scaffolds. The 
fibrin hydrogel scaffolds were prepared by mixing thrombin-
conjugated nanoparticles dispersed in an aqueous solution 
with a fibrinogen aqueous solution containing CaCl2, Factor 
XIII, aprotinin, growth factor-conjugated γ-Fe2O3 nanopar-
ticles, and the desired cells for cultivation.
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Figure 1 Physical and covalent conjugation of thrombin and bFGF to the γ-Fe2O3 nanoparticles. ≈, ∼, and – are symbols for precipitation, physical binding and covalent binding 
of various ligands to the γ-Fe2O3 nanoparticles, respectively.
Abbreviation: bFGF, basal fibroblast growth factor.
Figure 2 HRTEM images of the γ-Fe2O3 (A and B), γ-Fe2O3≈BSA (C) and γ-Fe2O3≈   
BSA∼Thrombin (D) nanoparticles placed on lacy grids. These images demonstrate 
the gelatin (A and B), gelatin≈BSA (C) and gelatin≈BSA∼Thrombin (D) coatings on 
the crystalline γ-Fe2O3 core of the nanoparticles.
Abbreviations: HRTEM, high-resolution transmission electron microscopy; BSA, 
bovine serum albumin.
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It should be noted that the magnetic scaffolds described 
in this manuscript are different from those described in 
the literature. To date, magnetic scaffolds were prepared 
by insertion of nonactive iron oxide nanoparticles to 
nonmagnetic scaffolds, eg, by dip-coating of porous collagen 
or hydroxyapatite scaffolds in aqueous ferrofluids containing 
iron oxide nanoparticles,17,19 or by in situ development of 
iron oxide nanoparticles in hydrogels.20,21 In contrast, our 
magnetic scaffolds were prepared by in situ interaction 
of magnetic thrombin-conjugated nanoparticles with 
fibrinogen.
In this study, adult rat NOM cells were chosen for culture 
in the scaffolds. Immunofluorescent staining of the NOM 
cells grown in stationary cultures in two dimensions, before 
being transferred to the magnetic fibrin scaffolds (Figure 3), 
indicates that the NOM cells cultures are composed of various 
cells: glial OECs (positively stained with mouse anti-S100B), 
neuronal cells (positively stained with rabbit anti-β3Tub and 
rabbit anti-NF), and stem and progenitor cells (positively stained 
with mouse anti-nestin). These results are in agreement with 
previous publications indicating that NOM tissue is a hetero-
geneous complex.35 Moreover, recent studies indicate that the 
transplantation of the “pure” OEC population is insufficient 
for attaining complete recovery of spinal cord injuries. A better 
recovery of the structure, and sensory and motor functions 
of an injured spinal cord can be attained using a complex of 
NOM cells, including, apart from the OECs, multipotent stem 
and progenitor cells.35
The clotting time of the fibrin hydrogel depends mainly on 
the concentration of the fibrinogen, thrombin and CaCl2.5,6,47 
In our developed formulation, the clotting time is about 
2 minutes. This period of time enables to be mixed the NOM 
cells with all the ingredients of the fibrin hydrogel scaffolds, 
and inserted into silicon rubber molds of desired shapes, 
or in tubes, before clotting. Generally, the fibrin hydrogel 
structure may vary between the extremes of “fine, transpar-
ent” and “coarse, turbid”.48 The fibrin gel structure is mainly 
determined by the thrombin and fibrinogen concentrations, 
but is also affected by other factors such as proteins and 
ions. For example, in the presence of albumin or fibronectin 
the morphology of the fibrin fiber network is coarser than 
in a purified fibrinogen-thrombin system.49 Calcium ions 
concentration is also such a modulating factor.5,49 Our pro-
duced magnetic fibrin hydrogel scaffolds have a high degree 
of transparency and a 3D structure. The transparency of the 
Figure 3 Immunofluorescence double staining of NOM cells cultured for 21 days in 2D stationary culture, prior to their seeding in the magnetic fibrin scaffolds. (A1) S100B 
(glia marker in red); (A2) NF (neuronal marker in green); (A3) merge of S100B and NF. (B1) Nestin (neuronal precursor marker in red); (B2) β3Tub (neuronal marker in 
green); (B3) merge of nestin and β3Tub. The nuclei of the cells were dyed in blue with DAPI.
Abbreviations: NOM, nasal olfactory mucosa; 2D, two-dimensional; S100B, 100% soluble calcium-binding protein B; NF, neurofilament; β3Tub, beta III tubulin; DAPI, 
4′,6-diamindo-2-phenylindole. 
Table 1 The concentrations and the conjugation yields of the 
thrombin and the bFGF bound to the γ-Fe2O3 nanoparticles
The bioactive  
nanoparticles
[Bound protein]  
[μg(protein)/ 
mg(nanoparticles)]
Conjugation   
yield  
(weight%)
γ-Fe2O3≈BSA∼Thrombin 97.5 ± 1.4 97.5 ± 1.4
γ-Fe2O3-bFGF 95.4 ± 1.9 95.4 ± 1.9
γ-Fe2O3≈HSA∼bFGF 96.9 ± 1.6 96.9 ± 1.6
Notes: The calculations of the conjugation yield and concentration were accom-
plished as described in the experimental section. ∼ and – are symbols for physical 
and covalent bindings, respectively of the bFGF to the γ-Fe2O3 nanoparticles.
Abbreviations: bFGF, basal fibroblast growth factor; BSA, bovine serum albumin; 
HSA, human serum albumin.
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scaffolds enables a microscopic observation of the cells dur-
ing their 3D growth in the scaffolds by light or a fluorescence 
microscope. However, it should be noted that when using a 
standard phase-contrast microscope it is possible to obtain 
sharp images only of cells at a particular plane of focus and 
not of the entire 3D pattern within the scaffolds.
To illustrate the efficiency of the magnetic fibrin hydro-
gel scaffolds as a matrix for cell adhesion, purified NOM 
cells were seeded on top of the fibrin hydrogel scaffolds, 
in comparison to their seeding on PLL-coated dishes or 
noncoated culture plates (control). Figure 4 demonstrates 
that the magnetic fibrin hydrogel scaffolds promoted the 
adhesion of the NOM cells significantly better than the 
PLL and the noncoated control surfaces (P , 0.01). These 
measurements indicate that in 2, 4, 6, and 24 hours post-
seeding, the amount of cells adhering to the fibrin scaffolds 
was 2.7, 3.0, 3.4, and 3.6 times higher than that obtained 
for the PLL group, and 6.2, 3.3, 3.4, and 3.6 times higher 
than that of the control group, respectively. The advantage 
of the magnetic fibrin hydrogel scaffolds for cell adhesion 
is probably due to the fibrin component, which naturally 
contains sites for cell binding. Therefore, it has been inves-
tigated as a substrate for cell adhesion, spreading, migration, 
and proliferation.5,6 It should be noted that the cell adhesion 
capacity of the scaffolds can be enhanced by the integra-
tion of adhesive molecules such as laminin and fibronectin 
within the scaffolds.3
The magnetic fibrin hydrogel scaffolds are biodegrad-
able. The duration of the degradability can be vary between 
a few days up to a few months, depending on various fac-
tors, eg, the density of seeded cells as well as the optimal 
concentrations of fibrinogen, thrombin, Ca++ ions, factor 
XIII, and aprotinin (a proteases inhibitor that slows down 
the degradation of the fibrin scaffold).50 The concentrations 
of these components also affect cell proliferation, migra-
tion, and differentiation within the fibrin scaffolds.47,50,51 In 
experiments that lasted over a month, we illustrated that our 
developed fibrin scaffolds containing the NOM cells in it 
are stable. During that time the NOM cells were grown in 
the scaffolds, proliferated and differentiated into neuron-like 
bipolar cells organized in 3D interconnected networks, as 
shown by SEM image (Figure 5), and later by phase-contrast 
microscopy (Figure 11).
The detailed-structure of the magnetic fibrin hydrogel 
scaffolds is illustrated by high magnification SEM and TEM 
images, as shown in Figure 5. The SEM image indicates that 
the fibrin hydrogel scaffolds are composed of a 3D porous 
fiber network. The TEM image shows the attachment of a few 
thrombin-conjugated nanoparticles on the external surface of 
the fibrin fibers. The other part of the nanoparticles is   probably 
encapsulated within the fibrin scaffolds. We   presume that 
the porous structures facilitate oxygen penetration into the 
scaffolds, and the network structure enables the 3D growth 
of the cells along the fibers.
Control PLL Magnetic fibrin scaffolds
A
d
h
e
r
e
d
 
c
e
l
l
s
 
(
c
e
l
l
s
/
f
i
e
l
d
)
100
120
140
160
180
200
80
60
40
20
0
24
Incubation time (h)
62 4
Figure 4 Quantitative analysis of the NOM cells adhered to the magnetic fibrin scaffold coating, or PLL coating, or uncoated culture plate (control) at different time intervals 
post-seeding. NOM cells were seeded in 24-well culture plates coated with the magnetic fibrin hydrogel or with PLL, or uncoated wells. 2, 4, 6, and 24 h after the seeding the 
wells were rinsed with the culture medium to remove the non-adherent cells. Quantification of the number of the adherent cells was performed by phase-contrast microscope 
images of five random non-overlapping fields of each well. Cells were then counted using ImageJ software, and the average and the standard deviation were calculated.
Abbreviations: NOM, nasal olfactory mucosa; PLL, poly-L-lysine.
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Figure 5 TEM (A) and SEM (B and C) images of the magnetic fibrin hydrogel scaffolds in the absence (A and B) or presence (C) of NOM cells. The magnetic fibrin scaffolds 
were prepared by the interaction of thrombin-conjugated γ-Fe2O3 nanoparticles with fibrinogen as described in the experimental part. The arrows in (A) point to the 
thrombin-conjugated nanoparticles.
Abbreviations: NOM, nasal olfactory mucosa; SEM, scanning electron microscopy; TEM, transmission electron microscopy.
−10000 −5000 5000 0
−0.2
0.0
0.2
0.4
0.6
−0.4
−0.6
Magnetic field (Oe)
A
B
M
a
g
n
e
t
i
z
a
t
i
o
n
 
(
e
m
u
/
g
)
10000
Figure 6 Magnetization curves at room temperature of the magnetic fibrin hydrogel scaffolds containing 0.15% (A) and 1.5% (B) γ-Fe2O3 nanoparticles. (A) represents the 
magnetic fibrin hydrogel scaffolds containing the thrombin-conjugated γ-Fe2O3 nanoparticles only; (B) represents the magnetic fibrin hydrogel scaffolds containing in addition 
to the thrombin conjugated nanoparticles also the bFGF conjugated γ-Fe2O3 nanoparticles.
Abbreviation: bFGF, basal fibroblast growth factor.
The magnetic properties of the fibrin hydrogel scaffolds 
were examined by VSM (Figure 6). Figure 6A exhibits 
the magnetic properties of the fibrin hydrogel scaffolds 
containing 0.15 weight% iron oxide nanoparticles, 
prepared by the interaction of thrombin-conjugated 
γ-Fe2O3 nanoparticles with fibrinogen, as described in 
the experimental section. Figure 6B exhibits the magnetic 
properties of the fibrin hydrogel scaffolds containing 1.5 
weight% of the iron oxide nanoparticles. These scaffolds 
were prepared by the addition of bFGF-conjugated γ-Fe2O3 
nanoparticles to the magnetic fibrin scaffolds before their 
clotting, as described in the experimental section. The 
magnetization curves shown in Figure 6 illustrate that 
at room temperature both M(H) plots reach saturation 
around 2000 Oe. The saturation magnetizations of the 
fibrin scaffolds containing 0.15 (A) and 1.5 (B) weight% 
of the iron oxide nanoparticles are 0.05 and 0.5 emu/g, 
respectively. The 10-fold increase in the magnetization 
of these scaffolds is probably attributed to the 10-fold 
increase in concentration of the iron oxide nanoparticles 
within the scaffolds. In other words, the magnetization 
is proportional to the concentrations of the iron oxide 
nanoparticles within the scaffolds: the higher the 
concentration the higher is the saturation magnetization. 
The magnetic properties of the fibrin hydrogel scaffolds 
were also demonstrated in a simple way, by attracting 
both scaffolds described above to a common magnet, as 
shown in Figure 7.
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Effect of free bFGF and bFGF conjugated 
to the γ-Fe2O3 nanoparticles on the 
growth of NOM cells seeded in the 
magnetic fibrin hydrogel scaffolds
Recent experiments have shown that bFGF treatment 
improves locomotor function via axonal regeneration in 
transected rat spinal cords, and when combined with neuronal 
cell grafts, can further amplify axonal extension after injury.25 
Furthermore, various studies have shown that bFGF promotes 
neuron survival, spinal cord regeneration and stimulates the 
proliferation of neuronal precursor cells in cultures.27,30,31 
Our aim in this part of the study was to compare the effect 
of the free and the conjugated bFGF nanoparticles on the 
growth and proliferation of NOM cells seeded in magnetic   
fibrin hydrogel scaffolds. For this purpose, the cells were 
seeded in the scaffolds, in the presence or absence of the free 
or the conjugated-bFGF nanoparticles, either as dissociated 
cells or attached to the chitosan MCs. These MCs are porous 
and possess diameters ranging between 100 and 400 mm.52 
The chitosan has a unique polymeric cationic character that 
combines with the electronegative groups on the cell surface, 
which benefits cell adhesion, spreading, and growth. Further-
more, the porous microstructure gives the MCs much greater 
surface areas for cell cultures and provides efficient nutrition 
and oxygen supply to the seeded cells.52 It has already been 
proven that the chitosan MCs are a suitable substrate for 
the adhesion, growth, and differentiation of various cells, 
Figure 7 Attraction of the magnetic fibrin hydrogel scaffolds containing 0.15% (top pictures) or 1.5% (bottom pictures) of the γ-Fe2O3 nanoparticles to a magnet. The top pictures 
represent the magnetic fibrin hydrogel scaffolds containing the thrombin-conjugated γ-Fe2O3 nanoparticles only. The bottom pictures represent the magnetic fibrin hydrogel 
scaffolds containing in addition to the thrombin conjugated nanoparticles also the bFGF conjugated γ-Fe2O3 nanoparticles. The arrows point to the magnetic fibrin scaffolds.
Abbreviation: bFGF, basal fibroblast growth factor.
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Figure 9 Phase-contrast microscope images illustrating the effect of the free and conjugated bFGF on the migration and growth of the NOM cells from the cells/free or 
conjugated bFGF/MCs aggregates, 18 days after the cultivation of the cell aggregates in the magnetic fibrin hydrogel scaffolds. (A) exhibits the effect of the naked γ-Fe2O3 
nanoparticles (control), (B) the effect of the physically conjugated bFGF nanoparticles, (C) the effect of the covalently conjugated bFGF nanoparticles. The effect of the same 
concentration of the free factor as that of the conjugated bFGF, and 5 and 10 times higher is illustrated in images (D), (E), and (F), respectively.
Note: The asterisks indicate some of the NOM cells/bFGF-γ-Fe2O3/MCs aggregates.
Abbreviations: bFGF, basal fibroblast growth factor; MC, chitosan microcarriers; NOM, nasal olfactory mucosa.
Figure 8 SEM images illustrating the NOM cells attached to the bFGF-γ-Fe2O3/MCs aggregates before being transferred to the magnetic fibrin scaffolds. (B) represents higher 
magnifications of the circulated area shown in (A).
Abbreviations: bFGF, basal fibroblast growth factor; MC, chitosan microcarriers; NOM, nasal olfactory mucosa; SEM, scanning electron microscopy.
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eg, NOM cells, cerebral neurons, skeletal myoblasts, and 
cardiac cells.38,53,54
Figure 8 illustrates by SEM images the attachment of the 
NOM cells to the bFGF-γ-Fe2O3/MCs. Similar pictures were 
also observed for the free bFGF/MCs aggregates. The NOM 
cell/free- or bFGF-conjugated nanoparticle/MCs aggregates 
were then transferred for proliferation to the magnetic fibrin 
scaffolds.
Figure 9 demonstrates by typical phase-contrast micro-
scope images the effect of the free and bound-bFGF on the 
migration of the NOM cells from the MCs aggregates and their 
growth in the magnetic fibrin hydrogel scaffolds 18 days after 
their cultivation. Figure 9A, corresponding to the cell/γ-Fe2O3 
nanoparticle/MCs aggregates, shows MCs aggregates and few 
cells in the fibrin gel, indicating that the attachment of the 
naked (nonconjugated) γ-Fe2O3 nanoparticles to the cell/MCs 
aggregates did not induce significant proliferation and migra-
tion of the NOM cells in the magnetic fibrin hydrogel scaffolds. 
On the contrary, Figure 9B and C show that the attachment of 
either physical or covalently bFGF-conjugated nanoparticles to 
the cell/MCs aggregates significantly enhanced the migration 
and growth of the NOM cells in the magnetic fibrin hydrogel 
scaffolds. The beneficial effect of the bFGF-conjugated nano-
particles on the NOM cells’ growth and migration compared to 
that of the free factor at the same concentration, and 5 and 10 
times higher, is illustrated in Figure 9D, E and F, respectively. 
These figures clearly show that the number of the NOM cells 
migrated from the MCs aggregates to the fibrin scaffolds are 
substantially higher in the presence of the conjugated bFGF 
(Figure 9B and C). A similar effect as the covalently bound 
factor was observed only when the free bFGF was added at 
a 10 times higher concentration as compared to the bound 
factor (Figure 9F).
This observation may be due to the fact that the conju-
gation of bFGF to the nanoparticles increases its stability 
against inhibitors and proteolytic enzymes present in the 
culture, and thus prolongs its activity, compared to that of 
the free factor. A similar stabilization effect was reported 
previously by us for thrombin,9,42 glial cell-derived neu-
rotrophic factors (GDNF),55 Factor VII,46 and methotrexate56 
conjugated to the γ-Fe2O3 nanoparticles.
For a quantitative determination of the effect of free/
conjugated bFGF on the kinetics of the migration of the 
NOM cells from the MCs aggregates to the magnetic fibrin 
hydrogel scaffolds, the total number of cells in the fibrin 
scaffolds was counted using the ImageJ software. Figure 10 
illustrates the total number of cells migrated from the cell/
nonconjugated or bFGF-conjugated nanoparticle/MCs 
aggregates and from the cell/free bFGFs of different concen-
tration/MCs aggregates to the magnetic fibrin scaffolds, 5, 
11, and 18 days after cultivation in the magnetic fibrin scaf-
folds. As expected, this figure illustrates, for all cultures, an 
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Figure 10 Quantitative analysis of the NOM cells migrated from the cells/nonconjugated or bFGF-conjugated nanoparticles/MCs aggregates and from the cells/different 
concentrations of the free factor/MCs aggregates (same concentration as the conjugated factor and 5 and 10 times higher), 5, 11, and 18 days after the cultivation of the 
cell aggregates in the magnetic fibrin hydrogel scaffolds. The reported values are an average of measurements performed on at least three randomly nonoverlapping fields 
of each triplicate tested culture.
Note: ∼ and – are symbols for physical and covalent bindings, respectively, of the bFGF to the γ-Fe2O3 nanoparticles.
Abbreviations: bFGF, basal fibroblast growth factor; MC, chitosan microcarriers; NOM, nasal olfactory mucosa.
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Figure 11 Phase-contrast microscope images illustrating the three-dimensional growth, proliferation, and differentiation of the NOM cells in the magnetic fibrin hydrogel 
scaffolds 21 days postcultivation in the presence (A) and absence (B) of the bFGF-γ-Fe2O3 nanoparticles.
Abbreviations: bFGF, basal fibroblast growth factor; NOM, nasal olfactory mucosa.
  increasing number of NOM cells in the fibrin scaffolds as the 
time of cultivation increased. This figure also illustrates that 
the migration rate of the NOM cells from the MCs aggregates 
and their growth in the magnetic fibrin hydrogel scaffolds 
is according to the following order: γ-Fe2O3-bFGF slightly 
higher than the γ-Fe2O3∼bFGF (P . 0.05), while both are 
significantly higher than the γ-Fe2O3 (P , 0.05). For example, 
18 days after cultivation, the number of cells counted in the 
presence of the γ-Fe2O3-bFGF, γ-Fe2O3∼bFGF, and γ-Fe2O3 
nanoparticles was 257 ± 29, 204 ± 16, and 31 ± 6 cells/
field, respectively. Figure 10 also exhibits, as expected, the 
acceleration in the NOM cells’ migration and growth as the 
concentration of the free factor increases. However, the cell 
migration and growth rate in the presence of the free factor at 
the same concentration as the conjugated factor (free ×1), or 
even five times higher (×5), was significantly lower than that 
observed for the conjugated factor (P , 0.05). Only when 
the concentration of the free factor was 10 times higher than 
that of the conjugated factor (×10), similar cell migration 
rates were observed (P . 0.05). For example, 18 days after 
cultivation, the number of cells counted in the presence of 
the covalently-conjugated bFGF, free ×1, free ×5, and free 
×10 was 257 ± 29, 84 ± 15, 124 ± 11, and 237 ± 14 cells/
field, respectively.
Figure 11 illustrates by typical phase-contrast microscope 
images the 3D growth of dissociated NOM cells in the 
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magnetic fibrin scaffolds 21 days post cultivation in the pres-
ence (A) or absence (B) of the covalently bFGF-conjugated 
γ-Fe2O3 nanoparticles. During this period, the NOM cells in 
the presence of the bFGF-conjugated nanoparticles formed 
significantly bigger 3D networks composed mainly of tapered 
bipolar cells (A) than that observed in the absence of conju-
gated bFGF (B). These results are in good agreement with 
a previous publication that demonstrated the positive effect 
of bFGF on NOM cell proliferation and differentiation into 
neuron-like cells.28,29
Conclusion
The present manuscript describes the synthesis and character-
ization of novel magnetic fibrin scaffolds for cell engineering 
prepared by the interaction of thrombin-conjugated magnetic 
iron oxide nanoparticles with fibrinogen. In addition, this 
manuscript shows that the conjugation of bFGF, either cova-
lently or physically, to the γ-Fe2O3 nanoparticles significantly 
enhances the migration, growth, and differentiation of NOM 
cells seeded within the fibrin scaffolds compared to the same 
concentration, or even five times higher, of the free bFGF. In 
future work we plan to extend these studies to growth factors 
other than bFGF, eg, GDNF and NGF. In addition, we plan 
to use the optimal magnetic fibrin scaffolds containing the 
growing NOM cells and the growth factors conjugated nano-
particles as composite implants for the treatment of spinal cord 
transacted rats. Since these scaffolds have magnetic proper-
ties, we intend to monitor the healing process by MRI.
Acknowledgment/Disclosure
These studies were partially supported by a Minerva Grant 
(Microscale and Nanoscale Particles and Films). The authors 
also wish to thank the following: Mrs. Sara Neuman (NVR 
Research Ltd, Israel) for her help in this project; Dr Thomas 
Freier from Medovent GmbH Germany for the supply of 
chitosan MCs powder; Drs Langzam Yakob, and Judith Grin-
blat from the Electron Microscopy Unit   (Bar-Ilan University, 
Israel) for their help with the SEM, and HRTEM, to Dror 
Eliaz (Bar-Ilan University, Israel) for his help in obtaining the 
immunofluorescence images, and to Dr Igor Grinberg for his 
help with the graphic work. The authors report no conflicts 
of interest in this work.
References
1.  Ahmed TAE, Dare EV, Hincke M. Fibrin: a versatile scaffold for 
tissue engineering applications. Tissue Eng Part B Rev. 2008;14(2): 
199–215.
2.  Straley KS, Wong Po Foo C, Heilshorn SC. Biomaterial design 
strategies for the treatment of spinal cord injuries. J Neurotrauma. 
2010;27:1–19.
  3.  Qian L-M, Zhang Z-J, Gong A-H, et al. A novel biosynthetic hybrid 
scaffold seeded with olfactory ensheathing cells for treatment of spinal 
cord injuries. Chin Med J. 2009;122(17):2032–2040.
  4.  Uibo R, Laidmae I, Sawyer ES, Flanagan LA, Georges PC, Winer JP. 
Soft materials to treat central nervous system injuries: evaluation of 
the suitability of non-mammalian fibrin gels. Biochim Biophys Acta. 
2009;1793(5):924–930.
  5.  Laurens N, Koolwijk P, de-Maat MPM. Fibrin structure and wound 
healing. J Thromb Haemost. 2006;4:932–939.
  6.  Mosesson MW, Siebenlist KR, Meh DA. The structure and biological 
features of fibrinogen and fibrin. Ann NY Acad Sci. 2001;936:11–30.
  7.  Jesty J. The kinetics of inhibition of alpha-thrombin in human plasma. 
J Biol Chem. 1986;261(22):10313–10318.
  8.  Margel S, Sheichat L, Tennenbaum T, et al; Bar-Ilan University, Israel, 
assignee. Biological glues based on thrombin conjugated nanoparticles. 
US patent 7550282, 2009.
  9.  Ziv O, Lublin-Tennenbaum T, Margel S. Synthesis and characterization 
of thrombin conjugated γ-Fe2O3 magnetic nanoparticles for hemostasis. 
Adv Eng Mater. 2009;11(12):B251–B260.
  10.  Margel S, Gura S; Bar-Ilan University, Israel, assignee. Nucleation and 
growth of magnetic metal oxide nanoparticles and its use. US patent 
139638, 2006.
  11.  de Vries IJM, Lesterhuis WJ, Barentsz JO, et al. Magnetic resonance 
tracking of dendritic cells in melanoma patients for monitoring of cel-
lular therapy. Nat Biotechnol. 2005;23(11):1407–1413.
  12.  Hergt R, Hiergeist R, Hilger I, et al. Maghemite nanoparticles with very 
high AC-losses for application in RF-magnetic hyperthermia. J Magn 
Magn Mater. 2004;270(3):345–357.
  13.  Scherer F, Anton M, Schillinger U, et al. Magnetofection: enhancing 
and targeting gene delivery by magnetic force in-vitro and in-vivo. 
Gene Ther. 2002;9(2):101–109.
  14.  Perlstein B, Ram Z, Daniels D, et al. Convection-enhanced delivery 
of maghemite nanoparticles: increased efficacy and MRI monitoring. 
Neuro-Oncol. 2008;10(2):153–161.
  15.  Mouaziz H, Veyret R, Theretz A, Ginot F, Elaissari A. Aminodextran   
containing magnetite nanoparticles for molecular biology applications:   
preparation and evaluation. J Biomed Nanotechnol. 2009;5(2): 
172–181.
  16.  Medeiros SF, Santos AM, Fessi H, Elaissari A. Stimuli-responsive 
magnetic particles for biomedical applications. Int J Pharm. 
2011;403(1–2):139–161.
  17.  Ajeesh M, Francis B, Annie J, Harikrishna Varma P. Nano iron oxide-
hydroxyapatite composite ceramics with enhanced radiopacity. J Mater 
Sci Mater Med. 2010;21(5):1427–1434.
  18.  Plank C, Scherer F, Schillinger U, Bergemann C, Anton M. 
  Magnetofection: enhancing and targeting gene delivery with 
  superparamagnetic nanoparticles and magnetic fields. J Liposome Res. 
2003;13(1):29–32.
  19.  Bock N, Riminucci A, Dionigi C, et al. A novel route in bone tis-
sue engineering: magnetic biomimetic scaffolds. Acta Biomater. 
2010;6(3):786–796.
  20.  Hu S-H, Liu T-Y, Tsai C-H, Chen S-Y. Preparation and characterization 
of magnetic ferroscaffolds for tissue engineering. J Magn Magn Mater. 
2007;310(2, Part 3):2871–2873.
  21.  Sivudu KS, Rhee KY. Preparation and characterization of pH-responsive 
hydrogel magnetite nanocomposite. Colloids Surf A Physicochem Eng 
Asp. 2009;349(1–3):29–34.
  22.  Sasaki T, Iwasaki N, Kohno K, et al. Magnetic nanoparticles for 
improving cell invasion in tissue engineering. J Biomed Mater Res A. 
2008;86A(4):969–978.
  23.  Shimizu K, Ito A, Honda H. Enhanced cell-seeding into 3D porous 
scaffolds by use of magnetite nanoparticles. J Biomed Mater Res B 
Appl Biomater. 2006;77B(2):265–272.
  24.  Zhong YH, Bellamkonda RV. Biomaterials for the central nervous 
system. J R Soc Interface. 2008;5(26):957–975.
  25.  Lu P, Tuszynski MH. Growth factors and combinatorial therapies for 
CNS regeneration. Exp Neurol. 2008;209(2):313–320.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1273
Magnetic fibrin hydrogel scaffolds for tissue engineeringInternational Journal of Nanomedicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-nanomedicine-journal
The International Journal of Nanomedicine is an international, peer-
reviewed journal focusing on the application of nanotechnology 
in diagnostics, therapeutics, and drug delivery systems throughout 
the biomedical field. This journal is indexed on PubMed Central, 
MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, 
Journal Citation Reports/Science Edition, EMBase, Scopus and the 
Elsevier Bibliographic databases. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
International Journal of Nanomedicine 2012:7
  26.  Bikfalvi A, Klein S, Pintucci G, Rifkin DB. Biological roles of fibroblast 
growth factor-2. Endocr Rev. 1997;18(1):26–45.
  27.  Morrison RS, Sharma A, De-Vellis J, Bradshaw RA. Basic fibroblast 
growth factor supports the survival of cerebral cortical neurons in 
primary culture. Proc Natl Acad Sci U S A. 1986;83(19):7537–7541.
  28.  MacDonald  KPA,  Murrell  WG,  Bartlett  PF,  Bushell  GR, 
  Mackay-Sim A. FGF2 promotes neuronal differentiation in explant 
cultures of adult and embryonic mouse olfactory epithelium. J Neurosci 
Res. 1996;44(1):27–39.
  29.  Murrell W, Bushell G, Livesey J, et al. Neurogenesis in adult human. 
NeuroReport. 1996;7:1189–1194.
  30.  Knusel B, Michel P, Schwaber J, Hefti F. Selective and nonselective 
stimulation of central cholinergic and dopaminergic development in 
vitro by nerve growth factor, basic fibroblast growth factor, epidermal 
growth factor, insulin and the insulin-like growth factors I and II.   
J Neurosci. 1990;10(2):558–570.
  31.  Huang Y-C, Huang Y-Y. Tissue engineering for nerve repair. Biomed 
Eng Appl Basis Comm. 2006;18:100–110.
  32.  Li S-H, Cai S-X, Liu B, Ma K-W, Wang Z-P, Li X-K. In vitro char-
acteristics of poly(lactic-co-glycolic acid) microspheres incorporating 
gelatin particles loading basic fibroblast growth factor. Acta Pharmacol 
Sin. 2006;27(6):754–759.
  33.  Zhang S, Uludag H. Nanoparticulate systems for growth factor delivery. 
Pharm Res. 2009;26(7):1561–1580.
  34.  Willerth SM, Sakiyama-Elbert SE. Cell therapy for spinal cord 
regeneration. Adv Drug Deliv Rev. 2008;60(2):263–276.
  35.  Viktorov I, Savchenko E, Ukhova O, Alekseyeva N, Chekhonin V. 
Multipotent stem and progenitor cells of the ofactory epithelium. Bull 
Exp Biol Med. 2006;142(4):495–502.
  36.  Fouad K, Schnell L, Bunge MB, Schwab ME, Liebscher T, Pearse DD.   
Combining schwann cell bridges and olfactory-ensheathing glia grafts 
with chondroitinase promotes locomotor recovery after complete 
transection of the spinal cord. J Neurosci. 2005;25(5):1169–1178.
  37.  Alexander CL, Fitzgerald UF, Barnett SC. Identification of growth fac-
tors that promote long-term proliferation of olfactory ensheathing cells 
and modulate their antigenic phenotype. Glia. 2002;37(4):349–364.
  38.  Rochkind S, Shahar A, Fliss D, et al. Development of a tissue-engineered 
composite implant for treating traumatic paraplegia in rats. Eur Spine J. 
2006;15(2):234–245.
  39.  Mackay-Sim A, St John JA. Olfactory ensheathing cells from the 
nose: Clinical application in human spinal cord injuries. Exp Neurol. 
2011;229(1):174–180.
  40.  Ziv O, Avtalion RR, Margel S. Immunogenicity of bioactive magnetic 
nanoparticles: natural and acquired antibodies. J Biomed Mater Res A. 
2008;85(4):1011–1021.
  41.  Svoboda J. Magnetic Techniques for The Treatment of Materials. 
London: Kluwer Academic Publishers; 2004.
  42.  Ziv-Polat O, Topaz M, Brosh T, Margel S. Enhancement of incisional 
wound healing by thrombin conjugated iron oxide nanoparticles. 
  Biomaterials. 2010;31(4):741–747.
  43.  Bradford M. A rapid and sensitive method for the quantitation of 
microgram quantities of protein utilizing the principle of protein-dye 
binding. Anal Biochem 1976;72:248.
  44.  Margel S, Lublin-Tennenbaum T, Gura S, et al. Synthesis and char-
acterization of nano- and micron-sized iron oxid and iron particles 
for biomedical applications. In: Zborowski M, Chalmers JJ, editors. 
Book series: Laboratory Techniques in Biochemistry and Molecular 
Biology, Volume 32: Magnetic Cell Separation. Amsterdam: Elsevier; 
2008:119–157.
  45.  Peters TJ. All About Albumin: Biochemistry, Genetics and Medical. 
San Diego, CA: Academic Press Inc; 1996.
  46.  Shafir G, Galperin A, Margel S. Synthesis and characteriza-
tion of recombinant factor VIIa-conjugated magnetic iron oxide 
nanoparticles for hemophilia treatment. J Biomed Mater Res A. 
2009;91A(4):1056–1064.
  47.  Rowe SL, Lee S, Stegemann JP. Influence of thrombin concentration 
on the mechanical and morphological properties of cell-seeded fibrin 
hydrogels. Acta Biomater. 2007;3(1):59–67.
  48.  Ferry JD, Morrison PR. Preparation and properties of serum and plasma 
proteins VIII. The conversion of human fibrinogen to fibrin under vari-
ous conditions. J Amer Chem Sot. 1947;69:388–400.
  49.  Blomback B, Carlsson K, Fatah K, Hessel B, Procyk R. Fibrin in human 
plasma: Gel architectures governed by rate and nature of fibrinogen 
activation. Thromb Res. 1994;75(5):521–538.
  50.  Willerth SM, Arendas KJ, Gottlieb DI, Sakiyama-Elbert SE.   Optimization 
of fibrin scaffolds for differentiation of murine embryonic stem cells 
into neural lineage cells. Biomaterials. 2006;27(36):5990–6003.
  51.  Bensaid W, Triffitt JT, Blanchat C, Oudina K, Sedel L, Petite H.   
A biodegradable fibrin scaffold for mesenchymal stem cell 
transplantation. Biomaterials. 2003;24(14):2497–2502.
  52.  Martin Y, Eldardiri M, Lawrence-Watt DJ, Sharpe JR. Microcarriers 
and their potential in tissue regeneration. Tissue Eng Part B Rev. 
2011;17(1):71–80.
  53.  Shahar A, Reuveny S. Nerve and muscle cells on microcarriers in 
  culture. Vertrebrate Cell Culture I. Vol 34: Springer Berlin/Heidelberg; 
1987:33–55.
  54.  Shahar A, Reuveny S, David Y, Budu C, Shainberg A. Cerebral neurons, 
skeletal myoblasts, and cardiac muscle cells cultured on macroporous 
beads. Biotechnol Bioeng. 1994;43(8):826–831.
  55.  Green-Sadan T, Kuttner Y, Lublin-Tennenbaum T, et al. Glial cell 
line-derived neurotrophic factor-conjugated nanoparticles sup-
press acquisition of cocaine self-administration in rats. Exp Neurol. 
2005;194(1):97–105.
  56.  Corem-Salkmon E, Ram Z, Daniels D, et al. Convection-enhanced 
delivery of methotrexate-loaded maghemite nanoparticles. Int J   
Nanomedicine. 2011;6(1):1595–1602.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1274
Ziv-Polat et al